SURMOUNT-4 Trial Reveals What Happens When You Stop Tirzepatide

Last Updated: April 2025

When 670 adults in the SURMOUNT-4 trial stopped taking tirzepatide after an initial open-label period, they regained 14% of their body weight within 52 weeks—roughly half of what they'd lost. Those who continued the drug maintained their weight loss. That single divergence, published in JAMA in 2024 and further analyzed in JAMA Internal Medicine in 2025, settles the debate about whether these drugs require indefinite use: they do.

The trial design was straightforward. All participants received tirzepatide 10 mg or 15 mg weekly for 36 weeks during an open-label run-in period. Those achieving at least 5% weight loss—which was 96% of enrollees—were then randomized 1:1 to either continue tirzepatide or switch to placebo for 52 weeks. Researchers collected data from March 2021 to May 2023, with analysis extending through March 2025.

The continuation group lost an additional 5.5% of body weight during the 52-week maintenance period, bringing total weight reduction to approximately 25.3% from baseline. The withdrawal group regained weight steadily, ending the maintenance period at 9.9% below their starting weight. The math is brutal: stop the drug, lose more than half your progress.

Cardiometabolic Parameters Tracked Weight Changes

A post hoc analysis published in JAMA Internal Medicine examined what happened to metabolic markers as weight returned. Researchers divided the withdrawal group into tertiles based on degree of weight regain and tracked changes in waist circumference, systolic blood pressure, fasting glucose, triglycerides, and HDL cholesterol.

Those who regained the most weight—more than 13.3% from their post-run-in nadir—saw their waist circumference increase by 12.1 cm on average. Their systolic blood pressure rose 5.1 mmHg. Fasting glucose climbed 9.8 mg/dL. The study authors noted that "improvements in cardiometabolic parameters were largely maintained in participants who continued tirzepatide and progressively worsened with greater weight regain after withdrawal."

This wasn't subtle deterioration. The highest tertile of weight regainers essentially reversed their metabolic improvements in proportion to how much weight they put back on. Meanwhile, continuous users maintained or extended their gains across all measured parameters.

The Maintenance Dosing Question

SURMOUNT-4 used the same doses during maintenance as during initial weight loss: 10 mg or 15 mg weekly. No dose reduction. No tapering. The trial didn't test whether lower maintenance doses might prevent regain while reducing cost or side effects—a question that remains unanswered and economically significant.

Some clinicians have experimented with extended dosing intervals or reduced maintenance doses in practice, but without controlled trial data. The FDA-approved dosing for tirzepatide remains weekly administration at the therapeutic dose. The recent approval of a 4-dose KwikPen for monthly dispensing doesn't change the weekly injection schedule; it's a packaging convenience.

What SURMOUNT-4 proves is that therapeutic-dose continuation prevents regain. What it doesn't prove is whether that's the minimum effective approach. The trial wasn't designed to find the lowest effective maintenance dose—it was designed to show whether continuation matters at all. It does.

Metabolic Memory Doesn't Exist Here

One persistent hope in obesity pharmacotherapy is that substantial weight loss might reset metabolic setpoints, allowing patients to maintain lower weights without ongoing treatment. SURMOUNT-4 demolishes this notion for tirzepatide. The withdrawal group's weight trajectory was essentially linear upward throughout the 52-week period, with no plateau suggesting a new equilibrium.

The body defends its previous weight with remarkable tenacity. Tirzepatide works primarily through GLP-1 and GIP receptor agonism, reducing appetite and slowing gastric emptying. Remove the drug, and those effects disappear. Hunger returns. Metabolic rate decreases in response to weight loss, as it does with any caloric restriction. The result is predictable weight regain unless the drug continues suppressing those compensatory mechanisms.

Dr. Louis Aronne of Weill Cornell Medicine, an investigator on multiple tirzepatide trials, has stated publicly that "obesity is a chronic disease requiring chronic treatment." SURMOUNT-4 provides the longitudinal evidence supporting that clinical stance. The disease doesn't resolve with temporary treatment any more than hypertension or diabetes do.

Comparison With Other GLP-1 Withdrawal Studies

SURMOUNT-4 isn't the first withdrawal trial in this drug class, but it's the largest and longest for tirzepatide specifically. The STEP-4 trial examined semaglutide withdrawal using a similar design. Participants who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight over 48 weeks of follow-up.

Trial	Drug	Weight Loss Before Withdrawal	Weight Regained After Withdrawal (52 weeks)	Net Weight Loss at Trial End
SURMOUNT-4	Tirzepatide	20.9%	~11% (absolute)	9.9%
STEP-4	Semaglutide 2.4mg	10.6%	~7% (absolute)	5.6%

Both trials show the same pattern: substantial regain after discontinuation, preservation of weight loss with continuation. Tirzepatide's dual agonism at GLP-1 and GIP receptors produces greater initial weight loss than semaglutide's GLP-1-only mechanism, but it doesn't appear to create more durable weight reduction after withdrawal. The regain percentage is similar across both drugs.

What This Means for Real-World Prescribing

Insurance companies have seized on the chronic treatment requirement as justification for coverage restrictions. Many plans limit obesity medications to 12 or 24 months, despite trial evidence showing that discontinuation leads to regain. This creates a perverse situation where payers will cover repeated cycles of treatment and regain rather than continuous maintenance therapy, which would be more effective and likely more cost-effective long-term.

The argument against indefinite coverage typically invokes cost. Tirzepatide's list price is approximately $1,060 per month. Over a decade, that's $127,200 per patient. But the cost analysis rarely accounts for the expenses associated with obesity-related comorbidities: type 2 diabetes treatment averages $9,601 annually per patient according to the American Diabetes Association. Cardiovascular disease costs exceed $18,000 annually per affected individual per CDC data.

SURMOUNT-4's cardiometabolic data shows that weight regain brings metabolic deterioration. If tirzepatide prevents diabetes onset or cardiovascular events, the drug cost becomes partially offset by avoided disease costs. The 10-year cost-effectiveness models haven't been published yet, but they're coming. Payers who implement arbitrary duration limits are making coverage decisions without that analysis.

The OSA Indication and Expanding Use Cases

While SURMOUNT-4 focused on weight maintenance, the parallel SURMOUNT-OSA trial demonstrated marked reductions in apnea-hypopnea index scores—the measure of hourly breathing disruptions during sleep. Participants taking tirzepatide experienced reductions of approximately 50% in these events, regardless of whether they used continuous positive airway pressure devices.

FDA approved tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity in early 2024 based on this data. It's the first drug approved for this indication. But the OSA approval doesn't change the chronic treatment calculus. Sleep apnea doesn't stay resolved if the weight returns. The SURMOUNT-4 withdrawal data applies equally to cardiovascular benefits, diabetes prevention, and sleep apnea improvements: they persist with treatment and fade without it.

Tolerability During Extended Use

One concern with any chronic medication is whether side effects accumulate or worsen over time. SURMOUNT-4's continuation arm provided 88 weeks of total tirzepatide exposure (36-week run-in plus 52-week maintenance). Adverse event rates during the maintenance period were similar to the run-in period, with gastrointestinal effects remaining the most common complaints.

Approximately 6% of continuation-arm participants discontinued due to adverse events during the maintenance period, compared to 2% in the placebo arm. Nausea, diarrhea, and constipation were most frequently cited. These rates didn't increase over time, suggesting tolerance stabilizes after the initial titration period rather than degrading with prolonged exposure.

No new safety signals emerged during extended treatment. Pancreatitis rates remained low. Gallbladder-related events occurred in 2.2% of tirzepatide users versus 0.7% of placebo users, consistent with what's expected from rapid weight loss regardless of method. The safety profile during maintenance matched what was seen during initiation.

What SURMOUNT-4 Doesn't Tell Us

The trial's 52-week withdrawal period, while substantial, doesn't show whether weight regain eventually plateaus or continues indefinitely. Some participants were still gaining weight at the end of follow-up. Would they return fully to baseline weight given enough time? The trial doesn't answer this.

It also doesn't address whether intermittent treatment—stopping and restarting as needed—might work for some patients. Can someone who regains 10-15 pounds restart tirzepatide, re-lose that weight, and cycle this way long-term? The trial wasn't designed to test this approach, and the cardiovascular and metabolic costs of weight cycling remain unclear.

The participant population was 66.6% female and 76.2% White, limiting generalizability to more diverse populations. Average baseline BMI was 38.3 kg/m², meaning most participants had class II or class III obesity. Whether the withdrawal effects differ in people with class I obesity or overweight with metabolic complications isn't addressed.

The Regulatory Avoidance Angle

FDA's approval of tirzepatide for chronic weight management explicitly acknowledges that obesity is a chronic disease requiring ongoing treatment. The label doesn't specify treatment duration limits. Yet the agency continues to allow insurance companies to impose arbitrary coverage restrictions that contradict the chronic disease model.

This regulatory gap—where FDA approves drugs for chronic use but doesn't prevent payers from covering them only acutely—creates a treatment access problem that evidence alone can't solve. SURMOUNT-4 provides the data showing continuation works and withdrawal fails. What's missing is the regulatory or legislative framework that aligns coverage policy with clinical evidence.

Some patients have turned to compounded versions or international sources to maintain access when insurance coverage expires. This gray market emerged directly from the coverage-evidence disconnect. FDA has issued warnings about compounded GLP-1 agonists, particularly regarding dosing accuracy and sterility, but demand persists because the alternative is weight regain with its attendant health consequences.

SURMOUNT-4 proves that tirzepatide works as long as you take it and stops working when you don't. That's not a limitation of the drug—it's the nature of treating a chronic metabolic disease. The failure isn't pharmaceutical; it's systemic, residing in coverage policies that pretend obesity resolves with time-limited treatment when decades of evidence show it doesn't.

Sources

1. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.